The size of the North American anatomic pathology market was valued at USD 7.32 billion in 2022 and is estimated to be growing at a CAGR of 5.51% to reach USD 9.57 billion by 2027.
Anatomical pathology is a medical specialty concerned with diagnosing disease based on the macroscopic, microscopic, biochemical, immunologic, and molecular examination of organs and tissues.
Several factors such as the rise in cases of chronic diseases like cancer, increase in healthcare expenditure in the region, the high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players like Thermo Fisher and Agilent, coupled with a large number of funding programs by public agencies in the region are the driving forces of the growth of the anatomic pathology market in North America.
Additionally, increasing incidences of various health disorders and the rise in demand to have a complete diagnosis of an issue to ensure the best treatment for the patient are promoting market growth in North America. Growing focus on examining the cells and tissue samples in the laboratories, growth in the prevalence to deliver quality drugs, and increasing the geriatric population are the other factors expanding the market demand.
However, the dearth of skilled persons in monitoring the systems and the results quietly hinders the market's demand. In addition, the cost for installation and maintenance of the equipment needs massive amounts, which are very hard for small-scale industries. This attribute is also impeding the growth rate of the Anatomic pathology market in North America.
Impact of COVID-19 on the North American Anatomic Pathology market:
Globally, the COVID-19 pandemic has impacted every aspect of the medical diagnosis industry, including the anatomic pathology market. The number of consulting visits to hospitals and clinics has reduced significantly in the last few months before lockdown, despite emergency and OPD services being available in hospitals.
Due to the lockdown in the second quarter in many countries, surgeries have reduced considerably. The World Economic Forum survey found that 28 million elective surgeries and 38% of global cancer surgeries have been delayed or postponed. Consequently, the number of diagnostic tests, sales of anatomic pathology products have reduced during this quarter of 2020. Additionally, due to the increase in COVID- 19, pathology laboratories are now prioritizing and centering on COVID-19 tests.
Many countries have undergone lockdown relaxations in the last month, and most hospitals have resumed elective surgeries, increasing the number of diagnostic tests conducted. However, the anatomic pathology market's overall growth rate is less than the previous year due to the factors mentioned above.
This research report on the North American Anatomic Pathology Market has been segmented & sub-segmented into the following categories:
Regionally, the United States anatomic pathology market is expected to play a leading role in the North American market during the forecast period owing to the rise in the disposable income in many areas and growth in the demand for healthy lifestyles. In addition, increasing incidences of chronic diseases such as cancer and others are spurring the market's need. In addition, the rise in awareness over the availability of different diagnostic procedures by collecting cells and tissue samples through biopsy elevates the market's demand.
The Canadian anatomic pathology market is estimated to be at a healthy CAGR due to the rise in the availability of skilled persons due to increasing training institutes.
KEY MARKET PLAYERS:
North America Anatomy Pathology Market is exceptionally incoherent, and many big players exist in this region. Key Players of this market in the North American region include Thermo Fisher Scientific, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, NeoGenomics Laboratories, Inc., Danaher Corporation, and Agilent Technologies.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2.2 Diagnostics Lab
5.2.4 Physicians' Office Lab
5.2.5 Y-o-Y Growth Analysis, By End-User
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By End-User
5.3.8 Y-o-Y Growth Analysis, By Application
5.3.9 Market Attractiveness Analysis, By Application
5.3.10 Market Share Analysis, By Application
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Product
22.214.171.124 By Type End-User
126.96.36.199 By Application
6.1.4 Market Attractiveness Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Product
220.127.116.11 By Type End-User
18.104.22.168 By Application
6.1.5 Market Share Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Product
188.8.131.52 By Type End-User
184.108.40.206 By Application
6.2 United States
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 F. Hoffmann-La Roche AG
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 NeoGenomics Laboratories Inc.
8.3 Laboratory Corporation of America Holdings
8.4 Thermo Fisher Scientific
8.5 Quest Diagnostics Incorporated
8.6 Agilent Technologies
8.7 Danaher Corporation
8.8 Sakura Finetechnical Co. Ltd.
8.10 IBISWorld’s Pathology Services
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.